TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of $0.15, $0.07 better than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million versus the consensus estimate of $97.66 million.

Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024. We anticipate that our cash, cash equivalents and investment securities as of December 31, 2024, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.